EMMA (Emmaus Life Sciences) Total Assets: $18.70 Mil (As of Mar. 2026)


What is Emmaus Life Sciences Total Assets?

Emmaus Life Sciences EMMA Total Assets is $18.70 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Emmaus Life Sciences's Total Assets for the quarter that ended in Mar. 2026 was $18.70 Mil.

During the past 12 months, Emmaus Life Sciences's average Total Assets Growth Rate was -16.70% per year. During the past 3 years, the average Total Assets Growth Rate was -25.20% per year. During the past 5 years, the average Total Assets Growth Rate was -21.50% per year. During the past 10 years, the average Total Assets Growth Rate was 76.60% per year.

During the past 13 years, Emmaus Life Sciences's highest 3-Year average Total Assets Growth Rate was 561.10%. The lowest was -31.50%. And the median was -7.40%.

Total Assets is connected with ROA %. Emmaus Life Sciences's annualized ROA % for the quarter that ended in Mar. 2026 was -66.48%. Total Assets is also linked to Revenue through Asset Turnover. Emmaus Life Sciences's Asset Turnover for the quarter that ended in Mar. 2026 was 0.10.

Emmaus Life Sciences  (OTCPK:EMMA) Total Assets Explanation

Total Assets is connected with ROA %.

Emmaus Life Sciences's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-13.34/( (21.436+18.696)/ 2 )
=-13.34/20.066
=-66.48 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Emmaus Life Sciences's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=1.982/( (21.436+18.696)/ 2 )
=1.982/20.066
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Emmaus Life Sciences Total Assets Related Terms

Emmaus Life Sciences Total Assets Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Total Assets Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.73 48.23 35.18 23.60 21.44

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.48 23.34 20.76 21.44 18.70

Emmaus Life Sciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Emmaus Life Sciences's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=-63.608+85.044
=21.44

Emmaus Life Sciences's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=-67.86+86.556
=18.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $18.70 Mil mean?
Emmaus Life Sciences (EMMA) has a Total Assets of $18.70 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Total Assets too high?
Emmaus Life Sciences' current Total Assets is $18.70 Mil.
How does Emmaus Life Sciences' Total Assets compare to CERO and AGTX?
Emmaus Life Sciences' Total Assets of $18.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Total Assets is $18.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Total Assets is $18.70 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Total Assets is $18.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.